Dianthus Therapeutics (DNTH) Cash from Investing Activities (2017 - 2025)

Dianthus Therapeutics' Cash from Investing Activities history runs 9 years deep, the most recent figure standing at -$201.3 million for Q3 2025.

• In Q3 2025, Cash from Investing Activities rose 22.4% year-over-year to -$201.3 million; the TTM figure through Sep 2025 stood at -$183.1 million (up 32.65% YoY), while the FY2024 annual figure was -$286.8 million, down 1516.15% from the prior year.
• Cash from Investing Activities was -$201.3 million for Q3 2025 at Dianthus Therapeutics, down from $26.4 million in the prior quarter.
• In the past five years, Cash from Investing Activities ranged from a high of $29.9 million in Q2 2021 to a low of -$259.4 million in Q3 2024.
• Historically, Cash from Investing Activities has averaged -$23.3 million across 5 years, with a median of -$5.5 million in 2024.
• The sharpest annual moves came in 2023 and 2024: Cash from Investing Activities soared 17048.84% in 2023, then tumbled 2154.36% in 2024.
• A 5-year view of Cash from Investing Activities shows it stood at -$10.3 million in 2021, then slipped by 22.69% to -$12.7 million in 2022, then soared by 34.96% to -$8.2 million in 2023, then sank by 180.56% to -$23.1 million in 2024, then plunged by 770.94% to -$201.3 million in 2025.
• The last three Cash from Investing Activities figures came in at -$201.3 million (Q3 2025), $26.4 million (Q2 2025), and $14.8 million (Q1 2025), per Business Quant data.